Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GNC-038 in relapsed or refractory diffuse large B-cell lymphoma
CTR20212755Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emfizatamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose-limiting toxicity, maximum tolerated dose, or maximum administered dose and Treatment-emergent adverse events. Started Aug 2022; status: active.
02
Drugs
emfizatamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20212755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212755.